Amphastar Pharmaceuticals Inc (AMPH)
44.54
+0.45
(+1.02%)
USD |
NASDAQ |
Nov 21, 16:00
44.54
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.142B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -22.09% |
| Valuation | |
| PE Ratio | 14.85 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.231 |
| Price to Book Value | 2.943 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.82 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 49.92% |
Profile
| Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |
| URL | https://www.amphastar.com |
| Investor Relations URL | https://ir.amphastar.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 28, 2025 (est.) |
| Last Earnings Release | Nov. 06, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |
| URL | https://www.amphastar.com |
| Investor Relations URL | https://ir.amphastar.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 28, 2025 (est.) |
| Last Earnings Release | Nov. 06, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |